Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > June 24, 2022
Daily News
June 24, 2022
- Health Minister Visits Takeda Manufacturing Site for Novavax Jab, Stresses Need to Handle Diverse Modalities in Japan
June 24, 2022
- Ono Chief Pledges to Boost Compliance after Bribery Case
June 24, 2022
- Shipment Curbs Remain for Over 40% of Drugs Despite Sufficient Supply Volumes: FPMAJ Survey
June 24, 2022
- 25 Japan Drug Makers Log Combined 10.7% Growth in FY2021, 12 See Two-Digit Jumps: Tally
June 24, 2022
- JCR Executive Pay Tops 100 Million Yen for First Time in FY2021
June 24, 2022
- Japan Logs 496 Pharma Product Recalls in FY2021; Self-Inspections, COVID Drive Surge
June 24, 2022
- Please Come Back to the Office!
June 24, 2022
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…